Bortezomib for Injection 3.5 mg Powder Vial

Bortezomib for Injection is a powerful proteasome inhibitor used in the treatment of certain types of cancer, notably multiple myeloma and mantle cell lymphoma. This lyophilized powder, when reconstituted, delivers targeted therapy for managing complex hematologic malignancies.

Usage: Bortezomib is indicated for the treatment of patients with multiple myeloma and those with mantle cell lymphoma who have received at least one prior therapy. It is used as part of a comprehensive cancer treatment regimen.

Dosage:

• Standard Dosage: Administered as an intravenous (IV) bolus injection or subcutaneous injection at a recommended dose of 1.3 mg/m² twice weekly for two weeks, followed by a 10-day rest period (21-day treatment cycle).
• Dosage may vary based on specific patient conditions and response.

CDC Guidelines: Though the CDC does not provide specific dosing guidelines for Bortezomib, it emphasizes adherence to oncological treatment protocols and monitoring for adverse effects to ensure patient safety. Proper handling and disposal of chemotherapeutic agents are also recommended.

Details and Features:

• Strength: 3.5 mg per vial
• Formulation: Lyophilized powder for reconstitution
• Packaging: 8 mL vial
• Proteasome Inhibition: Targets and disrupts cancer cell growth
• Versatile Administration: Suitable for IV or subcutaneous use

Mechanism of Action: Bortezomib works by inhibiting the 26S proteasome, a protein complex involved in degrading ubiquitinated proteins. This inhibition disrupts various cellular processes, leading to apoptosis in cancer cells, particularly those with high protein turnover like myeloma cells.

Directions for Use:

• Reconstitute the powder with sterile saline following aseptic technique.
• Administer via appropriate route (IV or subcutaneous) as prescribed.
• Follow specific oncologist or healthcare provider protocols closely.

Warnings:

• Patients should be monitored for peripheral neuropathy, hematologic toxicity, and cardiac events.
• Contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.
• Use caution in patients with hepatic impairment.

Side Effects: Common side effects include:

• Fatigue
• Gastrointestinal symptoms (nausea, diarrhea)
• Thrombocytopenia
• Peripheral neuropathy
• Fever In case of serious adverse reactions, seek immediate medical intervention.

Bortezomib for Injection by Hikma represents advanced therapeutics in cancer care, offering efficacy and flexibility in treatment regimens for healthcare professionals and patients alike.